Stock Price Quote

OXYGENTA PHARMACEUTICAL LTD.

NSE : NABSE : 524636ISIN CODE : INE102E01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE89.48-1.82 (-1.99 %)
PREV CLOSE ( ) 91.30
OPEN PRICE ( ) 89.48
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 908
TODAY'S LOW / HIGH ( )89.48 89.60
52 WK LOW / HIGH ( ) 26.01108.64
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 27-11 1990
Management Info
Sai Sudhakar Vankineni - Chairman Sai Sudhakar Vankineni - Managing Director
Registered Office

Address Survey No. 252/1,Aroor Village,Sadasivapet Mandal,
Sangareddy,
Telangana-502291

Phone 08455-250080 / 25080

Email info@oxygentapharma.com / cs@oxygentapharma.com

Website www.oxygentapharma.com

Registrars Details
Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
Listing : BSE

NEWS

06Feb Updates on Open Offer
Mark Corporate Advisors Pvt Ltd. ("Manager to the Offer") has submitted..
31Jan Letter of Offer
Mark Corporate Advisors Pvt Ltd. ("Manager to the Offer") has submitted..
18Oct Oxygenta Pharmaceutical informs about
Oxygenta Pharmaceutical has informed about the certificate dated October..
03Oct Oxygenta Pharmaceutical informs about
Oxygenta Pharmaceutical has informed that it enclosed disclosure under R..
27Sep Oxygenta Pharmaceutical informs about
Oxygenta Pharmaceutical has informed that the exchange has received the..

Financials

in Millions
QTR Sep 24 ANNUAL 24
Net Profit-28.55-34.8000000000001
Gross Profit -27.74 -138.72
Operating Profit -14.23-96.5400000000001
Net Sales 147.54396.42

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Vimta Labs (BSE)
peergroup  1132.00 (8.21%)
M.Cap ( in Cr)2542.40
Procter&Gamble Healt (BSE)
peergroup  5338.15 (1.49%)
M.Cap ( in Cr)8908.56
Kwality Pharma (BSE)
peergroup  777.95 (10.82%)
M.Cap ( in Cr)809.34
Wockhardt (BSE)
peergroup  1515.10 (4.76%)
M.Cap ( in Cr)24630.80
Bajaj Healthcare (BSE)
peergroup  649.25 (9.91%)
M.Cap ( in Cr)2052.12

Shareholding Pattern

PROMOTERS 51.12%
NON-INSTITUTION 48.85%
MUTUAL FUNDS/UTI 0.03%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Oxygenta Pharmaceutical Ltd.

Oxygenta Pharmaceutical Ltd. was incorporated in the year 1990. Its today's share price is 89.48. Its current market capitalisation stands at Rs 330.93 Cr. In the latest quarter, company has reported Gross Sales of Rs. 396.42 Cr and Total Income of Rs.396.85 Cr. The company's management includes Aakanksha Sachin Dubey, Sravani Reddy Gantla, Sunil Vishram Chawda, Raghavender Rao Kanuganti, Dolly Mandhan, Bharath Reddy Guntuku, Padmaja Surapureddy, Sanagari Kondal Reddy, Vidya Sagar Devabhutuni, Sai Sudhakar Vankineni, Sai Sudhakar Vankineni.

It is listed on the BSE with a BSE Code of 524636 , NSE with an NSE Symbol of and ISIN of INE102E01018. It's Registered office is at Survey No. 252/1,Aroor Village,Sadasivapet MandalSangareddy-502291, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AM Reddy & DR Reddy, Gowri Shankar & Associates, VDNR & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.